QALQONSIMON BEZ SARATONI ZAMONAVIY INSTRUMENTAL TASHXISLASH USULLARI
Article Sidebar
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Main Article Content
Аннотация:
Ushbu tadqiqot qalqonsimon bez saratonini instrumental tekshiruvlar orqali tashxislash va ularning samaradorligini baholashdan iborat. Bu yerda akademik Y.X.To‘raqulov nomidagi RIEIAT markazida UTT, MRT va OFEKT/KT yordamida ularning qalqonsimon bez diagnostikasida tutgan o‘rni, afzalliklari va kamchiliklari o‘rganildi.
Article Details
Как цитировать:
Библиографические ссылки:
Shore SL. Thyroid Cancer. In: Vinjamuri S, editor. PET/CT in Thyroid Cancer. Cham: Springer International Publishing; 2018. p. 1-7. [Google Scholar]
Shore SL. Thyroid Cancer Pathology. In: Vinjamuri S, editor. PET/CT in Thyroid Cancer. Cham: Springer International Publishing; 2018. p. 9-13. [Google Scholar]
Haymart MR, Banerjee M, Reyes-Gastelum D, et al. Thyroid Ultrasound and the Increase in Diagnosis of Low-Risk Thyroid Cancer. J Clin Endocrinol Metab 2019;104:785-92. 10.1210/jc.2018-01933 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol 2016;12:646-53. 10.1038/nrendo.2016.110 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA 2017;317:1338-48. 10.1001/jama.2017.2719 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Lubitz CC, Sosa JA. The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients. Cancer 2016;122:3754-9. 10.1002/cncr.30201 [PubMed] [CrossRef] [Google Scholar]
Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7:569-80. 10.1038/nrendo.2011.142 [PubMed] [CrossRef] [Google Scholar]
Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014;120:3627-34. 10.1002/cncr.29038 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab 2010;95:5296-304. 10.1210/jc.2010-1087 [PubMed] [CrossRef] [Google Scholar]
Wylie D, Beaudenon-Huibregtse S, Haynes BC, et al. Molecular classification of thyroid lesions by combined testing for miRNA gene expression and somatic gene alterations. J Pathol Clin Res 2016;2:93-103. 10.1002/cjp2.38 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Sandler JE, Huang H, Zhao N, et al. Germline Variants in DNA Repair Genes, Diagnostic Radiation, and Risk of Thyroid Cancer. Cancer Epidemiol Biomarkers Prev 2018;27:285-94. 10.1158/1055-9965.EPI-17-0319 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Lew JI, Solorzano CC. Use of ultrasound in the management of thyroid cancer. Oncologist 2010;15:253-8. 10.1634/theoncologist.2009-0324 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2017;27:1341-6. 10.1089/thy.2017.0500 [PubMed] [CrossRef] [Google Scholar]
Wu Y, Xu T, Cao X, et al. BRAF (V600E) vs. TIRADS in predicting papillary thyroid cancers in Bethesda system I, III, and V nodules. Cancer Biol Med 2019;16:131-8. 10.20892/j.issn.2095-3941.2018.0291 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Zhu J, Li X, Wei X, et al. The application value of modified thyroid imaging report and data system in diagnosing medullary thyroid carcinoma. Cancer Med 2019;8:3389-400. 10.1002/cam4.2217 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Grant EG, Tessler FN, Hoang JK, et al. Thyroid Ultrasound Reporting Lexicon: White Paper of the ACR Thyroid Imaging, Reporting and Data System (TIRADS) Committee. J Am Coll Radiol 2015;12:1272-9. 10.1016/j.jacr.2015.07.011 [PubMed] [CrossRef] [Google Scholar]
Tessler FN, Middleton WD, Grant EG. Thyroid Imaging Reporting and Data System (TI-RADS): A User's Guide. Radiology 2018;287:29-36. 10.1148/radiol.2017171240 [PubMed] [CrossRef] [Google Scholar]
Persichetti A, Di Stasio E, Guglielmi R, et al. Predictive Value of Malignancy of Thyroid Nodule Ultrasound Classification Systems: A Prospective Study. J Clin Endocrinol Metab 2018;103:1359-68. 10.1210/jc.2017-01708 [PubMed] [CrossRef] [Google Scholar]
Ram N, Hafeez S, Qamar S, et al. Diagnostic validity of ultrasonography in thyroid nodules. J Pak Med Assoc 2015;65:875-8. [PubMed] [Google Scholar]
Brito JP, Gionfriddo MR, Al Nofal A, et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab 2014;99:1253-63. 10.1210/jc.2013-2928 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Chudgar AV, Shah JC. Pictorial Review of False-Positive Results on Radioiodine Scintigrams of Patients with Differentiated Thyroid Cancer. Radiographics 2017;37:298-315. 10.1148/rg.2017160074 [PubMed] [CrossRef] [Google Scholar]
Xue YL, Qiu ZL, Perotti G, et al. 131I SPECT/CT: a one-station imaging modality in the management of differentiated thyroid cancer. Clinical and Translational Imaging 2013;1:163-73. 10.1007/s40336-013-0020-4 [CrossRef] [Google Scholar]
Ahmed S, Horton KM, Jeffrey RB, Jr, et al. Incidental thyroid nodules on chest CT: Review of the literature and management suggestions. AJR Am J Roentgenol 2010;195:1066-71. 10.2214/AJR.10.4506 [PubMed] [CrossRef] [Google Scholar]
Hoang JK, Langer JE, Middleton WD, et al. Managing incidental thyroid nodules detected on imaging: white paper of the ACR Incidental Thyroid Findings Committee. J Am Coll Radiol 2015;12:143-50. 10.1016/j.jacr.2014.09.038 [PubMed] [CrossRef] [Google Scholar]
Abraham T, Schoder H. Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med 2011;41:121-38. 10.1053/j.semnuclmed.2010.10.006 [PubMed] [CrossRef] [Google Scholar]
Ciarallo A, Marcus C, Taghipour M, et al. Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. PET Clin 2015;10:265-78. 10.1016/j.cpet.2014.12.009 [PubMed] [CrossRef] [Google Scholar]
Song B, Wang H, Chen Y, et al. Magnetic resonance imaging in the prediction of aggressive histological features in papillary thyroid carcinoma. Medicine (Baltimore) 2018;97:e11279. 10.1097/MD.0000000000011279 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Noda Y, Kanematsu M, Goshima S, et al. MRI of the thyroid for differential diagnosis of benign thyroid nodules and papillary carcinomas. AJR Am J Roentgenol 2015;204:W332-5. 10.2214/AJR.14.13344 [PubMed] [CrossRef] [Google Scholar]
Yuan Y, Yue XH, Tao XF. The diagnostic value of dynamic contrast-enhanced MRI for thyroid tumors. Eur J Radiol 2012;81:3313-8. 10.1016/j.ejrad.2012.04.029 [PubMed] [CrossRef] [Google Scholar]
Varoquaux A, Rager O, Dulguerov P, et al. Diffusion-weighted and PET/MR Imaging after Radiation Therapy for Malignant Head and Neck Tumors. Radiographics 2015;35:1502-27. 10.1148/rg.2015140029 [PubMed] [CrossRef] [Google Scholar]
Binse I, Poeppel TD, Ruhlmann M, et al. Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT? Eur J Nucl Med Mol Imaging 2016;43:1011-7. 10.1007/s00259-015-3288-y [PubMed] [CrossRef] [Google Scholar]
Jentzen W, Phaosricharoen J, Gomez B, et al. Quantitative performance of (124)I PET/MR of neck lesions in thyroid cancer patients using (124)I PET/CT as reference. EJNMMI Phys 2018;5:13. 10.1186/s40658-018-0214-y [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Jadvar H, Chen X, Cai W, et al. Radiotheranostics in Cancer Diagnosis and Management. Radiology 2018;286:388-400. 10.1148/radiol.2017170346 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Budiawan H, Salavati A, Kulkarni HR, et al. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging 2013;4:39-52. [PMC free article] [PubMed] [Google Scholar]
Santhanam P, Solnes LB, Rowe SP. Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond. Med Oncol 2017;34:189. 10.1007/s12032-017-1051-x [PubMed] [CrossRef] [Google Scholar]
Marcus CD, Ladam-Marcus V, Cucu C, et al. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009;72:217-38. 10.1016/j.critrevonc.2008.07.012 [PubMed] [CrossRef] [Google Scholar]
Lalchandani UR, Sahai V, Hersberger K, et al. A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors. Curr Probl Diagn Radiol 2019;48:576-85. 10.1067/j.cpradiol.2018.07.016 [PubMed] [CrossRef] [Google Scholar]
Gilardi L, Grana CM, Paganelli G. Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging. European Journal of Nuclear Medicine and Molecular Imaging 2014;41:2090-2. 10.1007/s00259-014-2848-x [PubMed] [CrossRef] [Google Scholar]
Kim HD, Kim BJ, Kim HS, et al. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis. Korean J Intern Med 2019;34:608-17. 10.3904/kjim.2017.063 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
O JH , Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016;280:576-84. 10.1148/radiol.2016142043 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Min SJ, Jang HJ, Kim JH. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review. Oncotarget 2016;7:27848-54. 10.18632/oncotarget.8425 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
O JH , Wahl RL. PERCIST in Perspective. Nucl Med Mol Imaging 2018;52:1-4. 10.1007/s13139-017-0507-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Aras M, Erdil TY, Dane F, et al. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. Nucl Med Commun 2016;37:9-15. 10.1097/MNM.0000000000000401 [PubMed] [CrossRef] [Google Scholar]